Nektar Therapeutics NKTR Stock
Nektar Therapeutics Price Chart
Nektar Therapeutics NKTR Financial and Trading Overview
| Nektar Therapeutics stock price | 64.93 USD |
| Previous Close | 22.45 USD |
| Open | 22.47 USD |
| Bid | 18.71 USD x 100 |
| Ask | 25.2 USD x 100 |
| Day's Range | 21.61 - 22.66 USD |
| 52 Week Range | 6.45 - 37.38 USD |
| Volume | 335.3K USD |
| Avg. Volume | 1.85M USD |
| Market Cap | 376.29M USD |
| Beta (5Y Monthly) | 0.964 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.64 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 94.83 USD |
NKTR Valuation Measures
| Enterprise Value | 237.88M USD |
| Trailing P/E | N/A |
| Forward P/E | -28.246754 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4.312831 |
| Price/Book (mrq) | 19.647697 |
| Enterprise Value/Revenue | 2.726 |
| Enterprise Value/EBITDA | -1.741 |
Trading Information
Nektar Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.964 |
| 52-Week Change | 30.63% |
| S&P500 52-Week Change | 18.63% |
| 52 Week High | 37.38 USD |
| 52 Week Low | 6.45 USD |
| 50-Day Moving Average | 19.18 USD |
| 200-Day Moving Average | 14.98 USD |
NKTR Share Statistics
| Avg. Volume (3 month) | 1.85M USD |
| Avg. Daily Volume (10-Days) | 504.26K USD |
| Shares Outstanding | 17.3M |
| Float | 10.7M |
| Short Ratio | 0.24 |
| % Held by Insiders | 0.96% |
| % Held by Institutions | 61.83% |
| Shares Short | 1.16M |
| Short % of Float | 6.87% |
| Short % of Shares Outstanding | 6.72% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | March 31, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | -152.48% |
| Operating Margin (ttm) | -424.14% |
| Gross Margin | 74.60% |
| EBITDA Margin | -156.59% |
Management Effectiveness
| Return on Assets (ttm) | -26.79% |
| Return on Equity (ttm) | -189.45% |
Income Statement
| Revenue (ttm) | 87.25M USD |
| Revenue Per Share (ttm) | 6.24 USD |
| Quarterly Revenue Growth (yoy) | -51.70% |
| Gross Profit (ttm) | 65.1M USD |
| EBITDA | -136622000 USD |
| Net Income Avi to Common (ttm) | -133041000 USD |
| Diluted EPS (ttm) | -9.45 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 218.63M USD |
| Total Cash Per Share (mrq) | 17.62 USD |
| Total Debt (mrq) | 186.66M USD |
| Total Debt/Equity (mrq) | 1358.71 USD |
| Current Ratio (mrq) | 3.241 |
| Book Value Per Share (mrq) | 1.107 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -176874000 USD |
| Levered Free Cash Flow (ttm) | -47842876 USD |
Profile of Nektar Therapeutics
| Country | United States |
| State | CA |
| City | San Francisco |
| Address | 455 Mission Bay Boulevard South |
| ZIP | 94158 |
| Phone | 415 482 5300 |
| Website | https://www.nektar.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 61 |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Q&A For Nektar Therapeutics Stock
What is a current NKTR stock price?
Nektar Therapeutics NKTR stock price today per share is 64.93 USD.
How to purchase Nektar Therapeutics stock?
You can buy NKTR shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Nektar Therapeutics?
The stock symbol or ticker of Nektar Therapeutics is NKTR.
Which industry does the Nektar Therapeutics company belong to?
The Nektar Therapeutics industry is Biotechnology.
How many shares does Nektar Therapeutics have in circulation?
The max supply of Nektar Therapeutics shares is 19.02M.
What is Nektar Therapeutics Price to Earnings Ratio (PE Ratio)?
Nektar Therapeutics PE Ratio is now.
What was Nektar Therapeutics earnings per share over the trailing 12 months (TTM)?
Nektar Therapeutics EPS is -8.64 USD over the trailing 12 months.
Which sector does the Nektar Therapeutics company belong to?
The Nektar Therapeutics sector is Healthcare.
Nektar Therapeutics NKTR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23724.96 USD — |
+0.61
|
9.88B USD — | 23628.82 USD — | 23946.23 USD — | — - | 9.88B USD — |
| US Tech Composite Total Return XCMP | 29137.78 USD — |
+0.62
|
— — | 29019.72 USD — | 29409.52 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech Biotechnology Total Retu XNBI | 5830.62 USD — |
+1.2
|
— — | 5732.51 USD — | 5837.42 USD — | — - | — — |
| US Tech Global Select Market Com NQGS | 11620.1 USD — |
+0.59
|
— — | 11575.56 USD — | 11733.88 USD — | — - | — — |
| US Tech Biotechnology NBI | 5366.46 USD — |
+1.2
|
— — | 5276.16 USD — | 5372.71 USD — | — - | — — |
| US Tech Health Care IXHC | 1115.96 USD — |
+0.87
|
— — | 1099.74 USD — | 1117.62 USD — | — - | — — |
- {{ link.label }} {{link}}